Welcome to LookChem.com Sign In|Join Free
  • or
Acetamide, 2-(hydroxyimino)-N-(4-methoxy-2-nitrophenyl)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

172162-01-5

Post Buying Request

172162-01-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

172162-01-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 172162-01-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,1,6 and 2 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 172162-01:
(8*1)+(7*7)+(6*2)+(5*1)+(4*6)+(3*2)+(2*0)+(1*1)=105
105 % 10 = 5
So 172162-01-5 is a valid CAS Registry Number.

172162-01-5Relevant academic research and scientific papers

Oxindole-based intraocular pressure reducing agents

Zaryanova, Ekaterina V.,Lozinskaya, Nataly A.,Beznos, Olga V.,Volkova, Maria S.,Chesnokova, Nataly B.,Zefirov, Nikolay S.

, p. 3787 - 3793 (2017)

The study represents the new findings at the crossroads of chemistry and medicine, particularly between medicinal and organic chemistry and ophthalmology. In this work we describe how the chemical reactivity of indolinone scaffold may be used to create small molecule ligands with strong biological response comparable with and larger than that of endogenous hormone. The synthesis of oxindole-based melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) analogues was proposed and their ability to influence intraocular pressure (IOP) was studied in vivo. Time-dependent study revealed the prolonged effect (more than 6?h) of the lead-compound. This effect in combination with high IOP reducing effect (41?±?6%) in low concentrations of the active compound (0.1?wt%) and with high water solubility represents a great potential of low-cost oxindole derivatives as potent antiglaucoma agents.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

-

Page/Page column 67, (2010/11/03)

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

Induction of a ferroelectric S(C)* liquid crystal phase by an atropisomeric dopant derived from 4,4'-dihydroxy-2,2'-dimethyl-6,6'-dinitrobiphenyl

Yang,Campbell,Birch,Williams,Lemieux

, p. 9557 - 9561 (2007/10/03)

We report the induction of a ferroelectric S(C)* phase in two S(C) liquid crystal hosts using a novel chiral dopant (-)-1 that incorporates an atropisomeric core derived from 4,4'-dihydroxy-2,2'-dimethyl-6,6'-dinitrobiphenyl. The racemic dopant was synthe

Synthesis & characterization of C2-symmetric biphenyls as novel dopants for induced ferroelectric liquid crystal phases

Yang,Lemieux

, p. 247 - 253 (2007/10/02)

We report the synthesis of novel rod-like chiral dopants bearing a C2-symmetric biphenyl core with a large transverse dipole moment, and the induction of a FLC phase upon doping of such compounds into a SC host.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 172162-01-5